- Company
- K-biopharma starts trials with bispecific antibodies
- by Son, Hyung-Min Feb 27, 2024 05:45am
- Major global pharmaceutical companies have accomplished successful marketing of bispecific antibodies. Now, the Korean biopharmaceutical industry is also joining this challenge. Current bispecific antibodies include Roche’s Lunsumio and Columvi, Abbvie’s Epkinly, and Janssen’s Tecvayli. Korean companies are planning to evaluate the possibilit
- Company
- Reimbursement for novel CMV drug Livtencity imminent in KOR
- by Eo, Yun-Ho Feb 27, 2024 05:45am
- The novel cytomegalovirus drug Livtencity will soon receive reimbursement in Korea. According to industry sources, Takeda Pharmaceutical Company of Korea recently completed drug pricing negotiations with the National Health Insurance Service for its cytomegalovirus (CMV) drug Livtencity (maribavir). The drug is expected to be approved in
- Company
- Shingrix leads shingles vaccine mkt…occupies 44% of mkt
- by Chon, Seung-Hyun Feb 26, 2024 05:24am
- The new shingles vaccine, Shingrix, has risen to lead the market in its first year of sales. It quickly gained 44% of the market share with its strong shingles prevention effect despite its high price. Since the addition of Shingrix, the market has doubled in size. According to the drug research institution IQVIA, the shingles vaccine market
- Company
- Samsung Bioepis’s Eylea biosimilar Afilivu approved in KOR
- by Son, Hyung-Min Feb 26, 2024 05:24am
- Samsung Bioepis announced on the 23rd that it has obtained domestic approval for its Eylea biosimilar ‘Afilivu.’ The approval marks the 2nd ophthalmic disease treatment Samsung Bioepis has received approval for after being granted approval for its Lucentis biosimilar Amelivu. Eylea is a macular degeneration treatment developed by the m
- Company
- Eylea continues to lead AMD mkt despite new competition
- by Son, Hyung-Min Feb 26, 2024 05:24am
- The entry of new drugs in the macular degeneration treatment market made little impact on Eylea’s sales. Eylea continued to top the macular degeneration treatment market last year, posting sales of KRW 96.7 billion. The Eylea biosimilars Vabysmo and Lucentis, which were released last year, have shown little presence in the market yet.
- Company
- Kay Bae appointed as KRPIA chair, also overseeing NZ, AUS
- by Eo, Yun-Ho Feb 26, 2024 05:24am
- Kay Bae (53), Sanofi-Aventis Korea Country Lead, literally has become the ‘center’ of the pharmaceutical company. Bae, who was recently appointed as a Country Lead to manage subsidiaries including Korea, New Zealand, and Australia of the Sanofi Group, is appointed as a new Chair of the Korean Research-based Pharmaceutical Industry Ass
- Company
- New Alzheimer’s drug Leqembi closer to drug marketing
- by Eo, Yun-Ho Feb 26, 2024 05:24am
- A new Alzheimer’s treatment ‘Leqembi’ is expected to receive approval for marketing in Korea. The Ministry of Food and Drug Safety (MFDS) is conducting a final assessment of Leqembi (lecanemab), a drug jointly developed by Eisai and Biogen, for marketing approval. Leqembi’s application for approval was submitted last year, indicati
- Company
- Alecensa prepares to solidify its lead in lung cancer mkt
- by Son, Hyung-Min Feb 23, 2024 05:49am
- Alecensa is showing a strong position in the targeted therapy market for ALK-positive lung cancer in Korea. Last year, Alecensa generated KRW 34.9 billion in sales, far outpacing the runner-up, Takeda Alunbrig's KRW 13.6 billion. As the only ALK-targeted therapy that has demonstrated efficacy in early-stage lung cancer, Alecensa is likely to con
- Company
- Alteogen expands license agreement with MSD
- by Kim, Jin-Gu Feb 23, 2024 05:49am
- Alteogen officially announced on the 22nd that it will receive an additional USD 20 million (approximately KRW 26.7 billion) from the multinational pharmaceutical giant MSD under the terms of their modified agreement. In June 2020, Alteogen signed a non-exclusive licensing agreement with MSD for its proprietary human hyaluronidase technol
- Company
- 2 ADC drugs being discussed for reimb after Enhertu
- by Eo, Yun-Ho Feb 23, 2024 05:49am
- The two next-generation ADC drugs following ‘Enhertu’ draw attention as they are currently being considered reimbursement listing in South Korea. Gilead Science Korea’s Trodelvy (Sacituzumab govitecan), used to treat triple-negative breast cancer (TNBC), and Astellas Pharma Korea’s Padcev (enfortumab vedotin), used to treat bladder
